TransMedics Group, Inc. (TMDX) stock
Close on Nov 13, 2026Market cap $3.17BP/E 25.0Yield 0.00%
TransMedics Group, Inc. grew revenue 28.5% to $727.65M over the twelve months to Sep 30, 2026. Operating income fell 9.9% to $86.45M, moving the operating margin from 16.9% to 11.9%. Free cash flow was $44.70M, down 63.0% from a year earlier. At the latest close the market valued the company at $3.17B, 25.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.17B
- P/E ratio
- 25.0
- Price to sales
- 4.35
- Price to book
- 5.75
- Dividend yield
- 0.00%
- Free cash flow yield
- 1.41%
Fundamentals
- Revenue
- $727.65M
- Net income
- $144.45M
- EPS, diluted
- $3.65
- Free cash flow
- $44.70M
- Book value per share
- $13.49
- Diluted shares
- 41M
Trading
- Next earnings
- Feb 23, 2027 (estimated, during market hours)
- Previous close
- $92.00
- Open
- $92.39
- Day's range
- $91.17 – $94.28
- Volume
- 840,859
- Average volume (20 days)
- 1,235,129
- Index membership
- S&P SmallCap 600 (since Nov 2024), Russell 2000, Russell 3000
- Beta (5 years)
- 1.34
- 52-week range
- $60.10 – $156.00
- RSI (14 days)
- 65.9
- Volatility (1 year)
- 64.1%
- Relative volume
- 0.92×
- WACC
- 11.9%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | TMDX | S&P 500 | Difference | TMDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.5% | -3.0% | +18.5 pts | ||
| 3 months | +1.9% | -2.8% | +4.7 pts | ||
| Year to date | -24.9% | +11.5% | −36.4 pts | ||
| 1 year | -20.9% | +13.5% | −34.4 pts | ||
| 3 years | +53.2% | +77.7% | −24.5 pts | +15.3% | +21.1% |
| 5 years | +240.7% | +72.6% | +168.1 pts | +27.8% | +11.5% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TransMedics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About TransMedics
Electromedical & Electrotherapeutic Apparatus
TransMedics is a medical technology company that develops systems and services for organ transplantation. Its core product platform is the Organ Care System, a portable warm perfusion device designed to preserve donor hearts, lungs, and livers in a functioning state outside the human body. The system comprises an electromechanical console, single-use perfusion sets, and nutrient solutions. The company also offers the National OCS Program, providing outsourced organ procurement, perfusion management, and air and ground transport logistics. Its primary customers are hospital transplant programs and academic medical centers.
Company profile, executives and historyTransMedics stock: common questions
What is TransMedics's stock price?
TMDX closed at $91.38 on Nov 13, 2026, down 0.67% on the day. Over the past 52 weeks it traded between $60.10 and $156.00.
What is TransMedics's market cap?
TransMedics was worth $3.17B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is TMDX's P/E ratio?
TMDX trades at 25.0 times earnings, based on diluted earnings per share of $3.65 over the twelve months to Sep 30, 2026.
How much revenue does TransMedics make?
TransMedics reported revenue of $727.65M for the twelve months to Sep 30, 2026, up 28.5% from a year earlier.
Does TransMedics pay a dividend?
No. TransMedics has not paid a cash dividend over the last twelve months.
When does TransMedics report earnings next?
TransMedics is expected to report Q4 FY2026 results on Feb 23, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has TMDX stock performed over the past year?
Including dividends, TMDX returned -20.9% over the past year, against +13.5% for the S&P 500.
How many TMDX shares are sold short?
9M shares were sold short at the latest FINRA report, 26.64% of the float, or 10.2 days of average trading volume.
Who are TransMedics's competitors?
Companies most similar to TransMedics by business, industry and size include LIVN, INMD, ITGR, CNMD, UFPT.
See a number that looks wrong?